Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS), a leading performance beauty company, will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022. The event will feature members of its management team, with an audio webcast available on demand starting at 7:00 am ET. Evolus focuses on innovative products tailored for beauty consumers, highlighting its flagship product, Jeuveau^®, which is dedicated exclusively to aesthetics. More details are available on Evolus' website.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the H.C. Wainwright 24^th Annual Global Investment Conference.

Event:		H.C. Wainwright 24th Annual Global Investment Conference
Date:		Monday, September 12, 2022
Time:		Available on-demand starting at 7:00 am ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau^® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau^® is a registered trademark of Evolus, Inc.

Hi-Pure^™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005046/en/

Investor/Media Contact:

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

Tel: 949-966-1798

Email: david.erickson@evolus.com

Source: Evolus

FAQ

What event will Evolus, Inc. attend in September 2022?

Evolus, Inc. will participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

What time will Evolus' presentation be available during the conference?

The presentation will be available on demand starting at 7:00 am ET.

Where can I listen to the audio webcast of Evolus' presentation?

The audio webcast will be available on the investor relations section of Evolus' website.

What is Jeuveau® and how is it related to Evolus, Inc.?

Jeuveau® is Evolus' flagship product, a neurotoxin dedicated solely to aesthetic treatments.

What is the main focus of Evolus, Inc.?

Evolus, Inc. focuses on providing innovative beauty products through a customer-centric approach.